AU2008293542B9 - Therapeutic isoxazole compounds - Google Patents

Therapeutic isoxazole compounds Download PDF

Info

Publication number
AU2008293542B9
AU2008293542B9 AU2008293542A AU2008293542A AU2008293542B9 AU 2008293542 B9 AU2008293542 B9 AU 2008293542B9 AU 2008293542 A AU2008293542 A AU 2008293542A AU 2008293542 A AU2008293542 A AU 2008293542A AU 2008293542 B9 AU2008293542 B9 AU 2008293542B9
Authority
AU
Australia
Prior art keywords
alkyl
compound
aryl
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008293542A
Other languages
English (en)
Other versions
AU2008293542B2 (en
AU2008293542A1 (en
Inventor
Alan P. Kaplan
Terence P. Keenan
Andrew J. Mcriner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dart Neuroscience Cayman Ltd
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of AU2008293542A1 publication Critical patent/AU2008293542A1/en
Priority to AU2014202864A priority Critical patent/AU2014202864B2/en
Application granted granted Critical
Publication of AU2008293542B2 publication Critical patent/AU2008293542B2/en
Publication of AU2008293542B9 publication Critical patent/AU2008293542B9/en
Assigned to DART NEUROSCIENCE (CAYMAN) LTD. reassignment DART NEUROSCIENCE (CAYMAN) LTD. Request for Assignment Assignors: HELICON THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008293542A 2007-08-27 2008-08-26 Therapeutic isoxazole compounds Ceased AU2008293542B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014202864A AU2014202864B2 (en) 2007-08-27 2014-05-26 Therapeutic isoxazole compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96820507P 2007-08-27 2007-08-27
US60/968,205 2007-08-27
PCT/US2008/074353 WO2009029632A1 (en) 2007-08-27 2008-08-26 Therapeutic isoxazole compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014202864A Division AU2014202864B2 (en) 2007-08-27 2014-05-26 Therapeutic isoxazole compounds

Publications (3)

Publication Number Publication Date
AU2008293542A1 AU2008293542A1 (en) 2009-03-05
AU2008293542B2 AU2008293542B2 (en) 2014-06-05
AU2008293542B9 true AU2008293542B9 (en) 2014-08-07

Family

ID=40387754

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2008293542A Ceased AU2008293542B9 (en) 2007-08-27 2008-08-26 Therapeutic isoxazole compounds
AU2014202864A Ceased AU2014202864B2 (en) 2007-08-27 2014-05-26 Therapeutic isoxazole compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2014202864A Ceased AU2014202864B2 (en) 2007-08-27 2014-05-26 Therapeutic isoxazole compounds

Country Status (11)

Country Link
US (5) US8222243B2 (OSRAM)
EP (2) EP3311813B1 (OSRAM)
JP (3) JP5718053B2 (OSRAM)
KR (2) KR101567454B1 (OSRAM)
CN (2) CN104072489B (OSRAM)
AU (2) AU2008293542B9 (OSRAM)
CA (2) CA2696609C (OSRAM)
ES (2) ES2748599T3 (OSRAM)
IL (3) IL203910A (OSRAM)
MX (1) MX2010002258A (OSRAM)
WO (1) WO2009029632A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613859B8 (pt) 2005-07-26 2021-05-25 Bial Portela & Ca Sa inibidores da comt, seus usos, e composição farmacêutica
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
SI2481410T1 (sl) 2007-01-31 2017-01-31 Bial - Portela & Ca., S.A. Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom
JP5718053B2 (ja) * 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
RU2701731C2 (ru) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
WO2011076725A1 (en) * 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN102229606B (zh) * 2011-06-03 2014-07-02 浙江工业大学 含异噁唑杂环的2-甲基苯并呋喃类衍生物及制备与应用
CN102229603B (zh) * 2011-06-03 2014-07-02 浙江工业大学 含三唑杂环的2-甲基苯并呋喃类化合物及其制备与应用
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
ES2606630T3 (es) 2011-11-28 2017-03-24 Novartis Ag Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
BR112015022202A2 (pt) 2013-03-14 2017-07-18 Dart Neuroscience Cayman Ltd compostos substituídos de naftiridina e quinolina como inibidores da mao
MX370188B (es) 2013-03-14 2019-12-04 Dart Neuroscience Cayman Ltd Compuestos de piridina y pirazina sustituidos como inhibidores de pde4.
CN104016938B (zh) * 2014-05-28 2016-08-17 浙江工业大学 一种含苯硒基的噁二唑类化合物及其制备与应用
CN104016939B (zh) * 2014-05-28 2016-06-15 浙江工业大学 一种2-亚乙基-3-乙酰基-1,3,4-噁二唑类化合物及其制备与应用
CN107073296A (zh) * 2014-09-17 2017-08-18 达特神经科学(开曼)有限公司 Mao‑b抑制剂和康复
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
WO2016179434A1 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Systems and methods for cognitive testing
UY37623A (es) 2017-03-03 2018-09-28 Syngenta Participations Ag Derivados de oxadiazol tiofeno fungicidas
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
BR112019022137A2 (pt) 2017-05-04 2020-05-12 Basf Se Usos de compostos, compostos da fórmula i, composição agroquímica e método para combater fungos nocivos fitopatogênicos
UY38031A (es) * 2017-12-22 2019-07-31 Bayer Ag Hidroxiisoxazolinas y derivados de estos
US10902558B2 (en) * 2018-05-18 2021-01-26 Gopro, Inc. Multiscale denoising of raw images with noise estimation
US10853215B2 (en) * 2018-09-10 2020-12-01 Microsoft Technology Licensing, Llc Intelligent configuration management of user devices
WO2024187126A1 (en) * 2023-03-09 2024-09-12 Aquinnah Pharmaceuticals, Inc. Inhibitors of tdp-43 and tau aggregation

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935523A (en) * 1961-06-17 1963-08-28 Acraf New sulphamido-oxadiazoles
GB1051322A (OSRAM) * 1967-08-09
US3995048A (en) * 1975-10-20 1976-11-30 Sandoz, Inc. Isoxazolyl benzamides useful as tranquilizers and sleep-inducers
AU576868B2 (en) 1984-06-11 1988-09-08 E.I. Du Pont De Nemours And Company Thiophene and pyridine sulfonamides
JPS6183181A (ja) * 1984-06-11 1986-04-26 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− 除草剤性チオフエンスルホンアミド類およびピリジンスルホンアミド類
DE3602016A1 (de) 1985-12-05 1987-06-11 Bayer Ag Pyri(mi)dyl-oxy- und thio-benzoesaeure-derivate
DD265317A5 (de) * 1985-12-05 1989-03-01 Bayer Ag,De Herbizide und pflanzenwuchsregulierende mittel
US5204482A (en) 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
DE3929233A1 (de) * 1989-09-02 1991-03-07 Bayer Ag 5-heterocyclyl-pyridin-3-carbon-benzylamide und -anilide
DE4126937A1 (de) * 1991-08-10 1993-02-11 Basf Ag Salicyl(thio)etherderivate, verfahren und zwischenprodukte zu ihrer herstellung
GB2265371A (en) * 1992-03-06 1993-09-29 Shell Int Research Isoxazole compounds
US5246914A (en) * 1992-08-07 1993-09-21 Basf Aktiengesellschaft Salicyloyl (thio)ether derivatives, their preparation and intermediates for their preparation
ATE223390T1 (de) * 1995-02-13 2002-09-15 Searle & Co Substituierte isoxazole zur behandlung von entzündung
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2257196A1 (en) * 1996-06-06 1997-12-11 Morris Padgett Rorer Herbicidal pyridinyl and pyrazolylphenyl ketones
AU6320998A (en) * 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
PL336304A1 (en) 1997-04-16 2000-06-19 Abbott Lab 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors
JPH11139975A (ja) * 1997-08-26 1999-05-25 Sankyo Co Ltd Ａ型モノアミンオキシダーゼ阻害薬
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
JP4385414B2 (ja) 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
DE19904389A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
CA2402414A1 (en) * 2000-03-22 2001-09-27 Christopher Bayly Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
PL203161B1 (pl) 2000-04-21 2009-08-31 Shionogi & Co Pochodne oksadiazolu, kompozycja farmaceutyczna je zawierająca oraz zastosowanie pochodnej oksadiazolu do wytwarzania leku do leczenia raka
JP2001316378A (ja) * 2000-04-28 2001-11-13 Takeda Chem Ind Ltd ベンズアミド誘導体およびその用途
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1317453B1 (en) * 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
CA2438991C (en) * 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7223791B2 (en) 2001-06-26 2007-05-29 Takeda Pharmaceutical Company Limited Function regulator for retinoid relative receptor
JP2004536104A (ja) 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
TW200400035A (en) * 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
US7329401B2 (en) * 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
AU2003222648A1 (en) 2002-05-13 2003-12-02 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
CN1684957A (zh) 2002-08-02 2005-10-19 阿根塔发明有限公司 作为组蛋白脱乙酰酶抑制剂的取代的噻吩基－异羟肟酸
US8124330B2 (en) 2002-08-19 2012-02-28 Helicon Therapeutics, Inc. Screening methods for cognitive enhancers
AR043048A1 (es) * 2002-08-30 2005-07-13 Syngenta Participations Ag Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
DK1611112T3 (da) 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
KR100729883B1 (ko) * 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
WO2004089367A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
JPWO2005004021A1 (ja) 2003-07-07 2006-08-17 富士通株式会社 サービス提供装置、方法及びプログラム
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005058808A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
AU2004312193B2 (en) 2004-01-05 2008-09-25 Astrazeneca Ab Thiophene derivatives as CHK 1 inihibitors
BRPI0508140B1 (pt) * 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1742627A4 (en) * 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
BRPI0511993A (pt) * 2004-07-20 2008-01-22 Siena Biotech Spa compostos moduladores de receptores de acetilcolina nicotìnicos alfa7, composições farmacêuticas e usos terapêuticos dos mesmos
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
US7338967B2 (en) 2004-09-10 2008-03-04 Syngenta Limited Substituted isoxazoles as fungicides
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
JP2008522978A (ja) * 2004-12-07 2008-07-03 エナンタ ファーマシューティカルズ インコーポレイテッド ３，６−ビシクロライド
WO2006078577A1 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
JP2006316054A (ja) * 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd 高コンダクタンス型カルシウム感受性ｋチャネル開口薬
WO2006134481A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2007002559A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
AU2006287528A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds
PE20070589A1 (es) * 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CN101282936B (zh) * 2005-10-07 2012-05-16 橘生药品工业株式会社 氮化杂环化合物及包含其的药物组合物
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP1989185B8 (en) * 2006-02-28 2013-06-26 Dart NeuroScience LLC Therapeutic compounds
WO2007103456A2 (en) * 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
KR20090042971A (ko) * 2006-08-24 2009-05-04 욱크하르트 리서치 센터 항미생물 활성을 갖는 신규한 마크로라이드 및 케토라이드
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
JP5427769B2 (ja) 2007-03-30 2014-02-26 サノフイ Ｐｇｄｓ阻害剤としてのピリミジンヒドラジド化合物
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker

Also Published As

Publication number Publication date
US20120202786A1 (en) 2012-08-09
JP2017002062A (ja) 2017-01-05
CA2974477A1 (en) 2009-03-05
KR101669432B1 (ko) 2016-10-26
US20150336941A1 (en) 2015-11-26
EP3311813B1 (en) 2019-08-07
US9029397B2 (en) 2015-05-12
CA2696609A1 (en) 2009-03-05
IL232406A (en) 2017-03-30
KR20100046060A (ko) 2010-05-04
AU2014202864B2 (en) 2016-05-12
US20130053361A1 (en) 2013-02-28
EP2182809B1 (en) 2018-01-17
IL226702A0 (en) 2013-07-31
JP2010538001A (ja) 2010-12-09
ES2748599T3 (es) 2020-03-17
US8222243B2 (en) 2012-07-17
US9650349B2 (en) 2017-05-16
IL203910A (en) 2014-06-30
CN104072489B (zh) 2017-07-07
US10053467B2 (en) 2018-08-21
HK1147938A1 (en) 2011-08-26
AU2014202864A1 (en) 2014-06-19
CN101820764B (zh) 2014-06-04
JP5718053B2 (ja) 2015-05-13
JP6250746B2 (ja) 2017-12-20
US20090062252A1 (en) 2009-03-05
CA2974477C (en) 2019-12-31
EP2182809A4 (en) 2012-02-15
KR20150059810A (ko) 2015-06-02
IL226702A (en) 2015-09-24
EP2182809A1 (en) 2010-05-12
CN104072489A (zh) 2014-10-01
EP3311813A1 (en) 2018-04-25
AU2008293542B2 (en) 2014-06-05
CA2696609C (en) 2017-09-05
WO2009029632A1 (en) 2009-03-05
JP2015110666A (ja) 2015-06-18
CN101820764A (zh) 2010-09-01
AU2008293542A1 (en) 2009-03-05
US8921399B2 (en) 2014-12-30
ES2663517T3 (es) 2018-04-13
MX2010002258A (es) 2010-04-22
IL232406A0 (en) 2014-06-30
US20170204111A1 (en) 2017-07-20
KR101567454B1 (ko) 2015-11-09

Similar Documents

Publication Publication Date Title
AU2008293542B9 (en) Therapeutic isoxazole compounds
CA3179059A1 (en) Collagen 1 translation inhibitors and methods of use thereof
EP2513085B1 (en) Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands
AU2009355487C1 (en) Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands
HK1147938B (en) Therapeutic isoxazole compounds
HK1123545B (en) Therapeutic compounds
HK1123545A1 (en) Therapeutic compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DART NEUROSCIENCE (CAYMAN) LTD.

Free format text: FORMER APPLICANT(S): HELICON THERAPEUTICS, INC.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired